GERMITEC acquired by EURAZEO, TURENNE CAPITAL & KURMA PARTNERS

Zydus entered into exclusive negotiations to acquire a controlling 85.6% stake (block trade) in Amplitude Surgical from PAI Partners, the management and minority shareholders. The offer price is EUR6.25 per share, representing an 80.6% premium over the pre-announcement share price. Following the block acquisition, Zydus will launch a mandatory simplified tender offer (OPAS) to acquire the remaining shares and intends to delist the company (squeeze-out) if the 90% threshold is reached.

Laboratoire Polidis has completed its first-ever capital opening. Siparex Entrepreneurs and UI Investissement have joined the company as minority shareholders to support its next growth phase and formalize a new managerial transition.

This transaction is a strategic corporate carve-out and vertical integration wherein Novonesis fully acquires the sales and distribution activities of the Feed Enzyme Alliance from its long-term joint venture partner, dsm-firmenich. Supported by a fully committed debt financing package, this operation effectively dissolves the historical alliance, granting Novonesis absolute control over the entire commercial value chain. The primary strategic rationale underpinning this acquisition is to directly combine the acquirer's established innovation and production capabilities with the target's extensive global go-to-market network. This powerful consolidation will significantly accelerate Novonesis's market penetration, unlock substantial revenue synergies, and solidify its undisputed leadership position within the global animal nutrition and biosolutions industry.

The secondary buyout of 100% of Medical International Research by Quadrivio Group triggers the complete exit of the incumbent private equity sponsor Aksìa SGR. This ownership transition follows an operational phase marked by an annualized revenue expansion and the successful launch of subscription-based software services. The secondary transaction alters the capital structure to support a broader consolidation strategy amid rising global demand for decentralized respiratory diagnostics. The incoming capital is structured to fund geographic expansion into historically underpenetrated, highly solvent Northern European healthcare jurisdictions including Germany and the United Kingdom. Institutional debt backing for the buyout combines a super-senior revolving credit line with a private unitranche facility designed to provide immediate funding for strategic add-on acquisitions.

Didactic reorganized its shareholder base to accelerate its transformation into a European industrial leader. GENEO Capital Entrepreneur and UI Investissement acquired a majority stake, taking over from the previous sponsor. The transaction involves significant reinvestment from the President and his management team, alongside Bpifrance and MACSF.

EB Development (Consortium: NextStage AM & IK Partners) has successfully concluded its takeover bid for Eurobio Scientific, following the results of a reopened offer period. The consortium now holds 88.92% of the share capital and voting rights (including treasury shares). The offer was initiated to take the company private and provide the management team, led by Denis Fortier, with the flexibility to pursue an aggressive external growth strategy. While the bid secured a significant majority, the final participation fell just short of the 90% threshold required for a mandatory squeeze-out (retrait obligatoire). Consequently, the conditional additional price of €1.25 per share (linked to reaching the 90% mark) will not be paid to tendering shareholders. Despite remaining listed for the time being, the transaction effectively shifts Eurobio into a "private-equity-backed" development phase, allowing for deeper consolidation of the European in vitro diagnostics market.

Naxicap Partners has acquired a majority stake (over 60%) in Global D, marking the company’s first independent LBO following its carve-out from the Menix Group. The remaining capital is held by a dozen managers led by the executive team. The transaction follows a competitive auction process and includes a financing package provided by Capza (unitranche and PIK debt) alongside a capex line from Banque Palatine. This strategic "independence" move follows the parent group's divestment of other assets to industrial giants. The rationale for this new cycle is to support the firm’s internationalization and active buy-and-build strategy, targeting niche acquisitions with revenues between 5 million and 20 million euros to complement its existing technology and geographic reach.

Bansk Group completed the acquisition of 100% of PetIQ in an all-cash public-to-private transaction. PetIQ was delisted from Nasdaq upon closing and is now operated as a privately held company, with founder Cord Christensen continuing as CEO. The existing executive management team will continue to operate the business independently. The strategic rationale centres on accelerating PetIQ's mission of providing convenient and affordable pet healthcare, investing in marketing and innovation, and pursuing strategic bolt-on acquisitions — initiatives that Bansk believes are better executed outside the constraints of public market ownership.

Anjac reorganized its capital by welcoming KKR and Krefeld as minority shareholders, following a competitive process led by Rothschild & Co. The EUR450M investment allowed the exit of historical partners Andera Partners, Bpifrance, and IDIA. The Anjac family maintains a strong majority. The transaction was coupled with an extension of the existing syndicated credit line to fund future acquisitions.

Sanofi has announced the sale of 50% of its stake in Opella to the American fund CD&R. Opella Healthcare (formerly Sanofi Consumer Healthcare) is a company specializing in consumer healthcare products.